Biocon Biologics, Amgen Settle Patent Dispute, Clearing US Launch of Denosumab Biosimilars
MT Newswires Live
Oct 01
Biocon (NSE:BIOCON, BOM:532523) subsidiary, Biocon Biologics, has settled patent litigation with Amgen in the U.S. District Court of New Jersey, enabling the launch of its denosumab biosimilars, Bosaya and Aukelso, from Oct. 1, according to an Indian bourse filing on Wednesday.
Both products, approved by the US FDA in September with provisional interchangeability, are biosimilars to Amgen's Prolia and Xgeva used for osteoporosis and cancer-related bone conditions.
Settlement terms remain confidential.
Biocon shares rose over 1% in early trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.